More studies are still needed, but the development of Gal-3 inhibitors that can be administered alone or in conjunction with standard HNSCC treatments to increase their effectiveness is shown to be a promising strategy. This evidence concerns the gene LGALS3 and head and neck squamous cell carcinoma.